Publikationen in Zusammenarbeit mit Forschern von Hospital de la Santa Creu i Sant Pau (11)

2024

  1. Dual mTOR1/2 Inhibitor Sapanisertib (FTH-003/TAK-228) in Combination With Weekly Paclitaxel in Patients With Previously Treated Metastatic Urothelial Carcinoma: A Phase II Open-Label Study

    Clinical Genitourinary Cancer, Vol. 22, Núm. 5

  2. Induction avelumab followed by chemoimmunotherapy and maintenance versus chemotherapy alone as first-line therapy in cis-ineligible metastatic urothelial carcinoma (INDUCOMAIN): a randomized phase II study

    ESMO Open, Vol. 9, Núm. 9

2021

  1. Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1–Positive Advanced NSCLC

    Journal of Thoracic Oncology

2020

  1. Long-term outcomes and retreatment among patients with previously treated, programmed death-ligand 1‒positive, advanced non‒small-cell lung cancer in the KEYNOTE-010 study

    Journal of Clinical Oncology, Vol. 38, Núm. 14, pp. 1580-1591

2019

  1. Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: An updated analysis of keynote-010 trial

    Annals of Oncology, Vol. 30, Núm. 2, pp. 281-289

2018

  1. Radium-223 international early access program: Results from the Spanish subset

    Future Oncology, Vol. 14, Núm. 1, pp. 41-50

2017

  1. HIF pathway and c-Myc as biomarkers for response to sunitinib in metastatic clear-cell renal cell carcinoma

    OncoTargets and Therapy, Vol. 10, pp. 4635-4643

  2. Strategies to design clinical studies to identify predictive biomarkers in cancer research

    Cancer Treatment Reviews, Vol. 53, pp. 79-97

2016

  1. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial

    The Lancet, Vol. 387, Núm. 10027, pp. 1540-1550

2013

  1. Phase II trial of sequential subcutaneous interleukin-2 plus interferon alpha followed by sorafenib in renal cell carcinoma (RCC)

    Clinical and Translational Oncology, Vol. 15, Núm. 9, pp. 698-704

2011

  1. Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: Baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity

    Annals of Oncology, Vol. 22, Núm. 12, pp. 2646-2653